Biodefense & Pandemic Preparedness — December 24, 2025

CDC awarded firm-fixed-price deal to McKesson subsidiary for centralized vaccine distribution (NAICS 325412), obligated $152.8M with $68.4M outlayed and potential expansion to $8.1B via options through 2029.

Firm-fixed-price structure exposes McKesson to cost overruns through 2029 performance period.

Uncertainty in exercising $8.1B options beyond current $152.8M obligation, with limited outlay indicating potential funding delays.

Expansion from $152.8M to $8.1B via option exercises and potential extension to 2029 for recurring CDC vaccine distribution needs.

CDC prioritizes centralized distribution via large-scale, long-duration contracts in biodefense/pandemic preparedness.

{"entity"=>"McKesson Corporation", "reason"=>"Primary beneficiary of $152.8M obligated / $8.1B potential CDC contract in biodefense stream.", "trigger"=>"Option exercises or outlay acceleration signaling revenue ramp"}

{"entity"=>"CDC Office of Acquisition Services", "reason"=>"Source of high-value vaccine contracts with multi-year optionality.", "trigger"=>"New awards or modifications in biodefense stream"}